| Elucidating compound mechanism of action by network perturbation analysis JH Woo, Y Shimoni, WS Yang, P Subramaniam, A Iyer, P Nicoletti, ... Cell 162 (2), 441-451, 2015 | 370 | 2015 |
| A community computational challenge to predict the activity of pairs of compounds M Bansal, J Yang, C Karan, MP Menden, JC Costello, H Tang, G Xiao, ... Nature biotechnology 32 (12), 1213-1222, 2014 | 345 | 2014 |
| A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors MJ Alvarez, PS Subramaniam, LH Tang, A Grunn, M Aburi, G Rieckhof, ... Nature genetics 50 (7), 979-989, 2018 | 218 | 2018 |
| Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies C Deng, MR Lipstein, L Scotto, XO Jirau Serrano, MA Mangone, S Li, ... Blood, The Journal of the American Society of Hematology 129 (1), 88-99, 2017 | 126 | 2017 |
| PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens EC Bush, F Ray, MJ Alvarez, R Realubit, H Li, C Karan, A Califano, ... Nature communications 8 (1), 105, 2017 | 114 | 2017 |
| Dynamic diversity in drug discovery: Putting small-molecule evolution to work C Karan, BL Miller Drug Discovery Today 5 (2), 67-75, 2000 | 94 | 2000 |
| RNA-selective coordination complexes identified via dynamic combinatorial chemistry C Karan, BL Miller Journal of the American Chemical Society 123 (30), 7455-7456, 2001 | 87 | 2001 |
| Application of high-throughput screening to identify a novel αIIb-specific small-molecule inhibitor of αIIbβ3-mediated platelet interaction with fibrinogen R Blue, M Murcia, C Karan, M Jiroušková, BS Coller Blood, The Journal of the American Society of Hematology 111 (3), 1248-1256, 2008 | 82 | 2008 |
| Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19 H Liu, S Iketani, A Zask, N Khanizeman, E Bednarova, F Forouhar, ... Nature communications 13 (1), 1891, 2022 | 79 | 2022 |
| Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma S Jain, X Jirau-Serrano, KM Zullo, L Scotto, CF Palermo, SA Sastra, ... Clinical Cancer Research 21 (9), 2096-2106, 2015 | 63 | 2015 |
| Extending the Scope of Chromium− Manganese Redox-Coupled Reactions: A One-Pot Synthesis of Benzoxazoles A Hari, C Karan, WC Rodrigues, BL Miller The Journal of Organic Chemistry 66 (3), 991-996, 2001 | 60 | 2001 |
| A community challenge for a pancancer drug mechanism of action inference from perturbational profile data EF Douglass, RJ Allaway, B Szalai, W Wang, T Tian, A Fernández-Torras, ... Cell Reports Medicine 3 (1), 2022 | 49 | 2022 |
| TSH receptor signaling abrogation by a novel small molecule R Latif, RB Realubit, C Karan, M Mezei, TF Davies Frontiers in endocrinology 7, 130, 2016 | 46 | 2016 |
| Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma AM Sonabend, AS Carminucci, B Amendolara, M Bansal, R Leung, L Lei, ... Neuro-oncology 16 (9), 1210-1219, 2014 | 46 | 2014 |
| Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma G Ambrosini, C Do, B Tycko, RB Realubit, C Karan, E Musi, RD Carvajal, ... Cancer research 79 (9), 2415-2425, 2019 | 44 | 2019 |
| RABiT-II: Implementation of a high-throughput micronucleus biodosimetry assay on commercial biotech robotic systems M Repin, S Pampou, C Karan, DJ Brenner, G Garty Radiation research 187 (4), 502-508, 2017 | 43 | 2017 |
| RABiT-II-DCA: A fully-automated dicentric chromosome assay in multiwell plates E Royba, M Repin, S Pampou, C Karan, DJ Brenner, G Garty Radiation research 192 (3), 311-323, 2019 | 37 | 2019 |
| AI is a viable alternative to high throughput screening: a 318-target study Scientific reports 14 (1), 7526, 2024 | 34 | 2024 |
| Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators A Obradovic, C Ager, M Turunen, T Nirschl, M Khosravi-Maharlooei, ... Cancer Cell 41 (5), 933-949. e11, 2023 | 28 | 2023 |
| The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies JEL Diaz, ME Ahsen, T Schaffter, X Chen, RB Realubit, C Karan, ... Elife 9, e52707, 2020 | 28 | 2020 |
